Amgen Share Price

Amgen Share Price

NASDAQ: AMGN | Mega Cap | Healthcare
$436.05
-$3.05 (-0.69%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • Similar Stocks
  • FAQs

Amgen Stock Performance

Open
$443.05
Prev. Close
$439.10
Circuit Range
N/A
Day Range
$434.60 - $444.61
Year Range
$312.53 - $482.50
Volume
1,34,213
Average Traded
$439.45

Amgen Share Price Today

As of 21 November 2026, Amgen Inc.'s share price is $436.05. The stock opened at $443.05, compared to its previous close of $439.10. During today's trading session, Amgen Inc.'s share price traded between $434.60 and $444.61, with an average price of $439.60. Over the past 52 weeks, the stock has recorded a high of $482.50 and a low of $312.53. In terms of performance, Amgen Inc.'s share price has risen by 29.48% over the last six months and is up 26.24% on a year-on-year basis.

Amgen Share Price Chart

Line chart of the Amgen price trend over the selected period. The price fell overall, ranging from 434.74 to 444.98, ending at 435.98.
$434.60$444.61
L
Show Current Price
H

Amgen Stock Fundamentals & Key Indicators

Market Cap
$234.59B
PE Ratio (TTM)
25.28
Dividend Yield
2.26%
EPS (TTM)
$17.36
Revenue (TTM)
$36.75B
Return On Equity (TTM)
65.43%
Profit Margin
20.98%
Debt to Equity
3.76
Quarterly Earnings Growth YoY
190.23%

Amgen Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$9.87$8.62$10.05$10.37
Net Profit$1.33$1.82$2.38$3.86
Net Profit Margin13.48%21.11%23.68%37.22%
Income ChangeN/A36.84%30.77%62.18%

Amgen Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$26.32$28.19$33.42$36.75
Net Profit$6.55$6.72$4.09$7.71
Net Profit Margin24.89%23.84%12.24%20.98%
Income ChangeN/A2.60%-39.14%88.51%

Amgen Balance Sheet

All figures in USD Billion

Particulars2025202420232022
Non Current Assets61.5362.8166.8242.94
Current Assets29.0629.0330.3322.19
Total Assets90.5991.8497.1565.12
Non Current Liabilities56.4462.8672.5345.77
Current Liabilities25.4923.118.3915.69
Total Liabilities81.9385.9690.9261.46
Shareholders' Equity8.665.886.233.66

Amgen Cash Flow

Annually

All figures in USD Billion

Particulars2025202420232022
Operating10.011.58.59.7
Investing-1.9-1.1-26.2-6.0
Financing-10.9-9.421.1-4.0

Corporate Actions

Dividend
Ex-date: 20 Nov 2026

Dividend
Ex-date: 21 Aug 2026

Dividend
Ex-date: 15 May 2026

Dividend
Ex-date: 13 Feb 2026

Dividend
Ex-date: 21 Nov 2025

Dividend
Ex-date: 22 Aug 2025

Dividend
Ex-date: 16 May 2025

Dividend
Ex-date: 14 Feb 2025

Dividend
Ex-date: 18 Nov 2024

Dividend
Ex-date: 16 Aug 2024

Dividend
Ex-date: 16 May 2024

Dividend
Ex-date: 15 Feb 2024

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$466.06
$434.98
-6.63%
Oct 2026
$421.95
$465.88
+10.38%
Sep 2026
$432.49
$422.08
-3.40%
Aug 2026
$389.64
$436.92
+13.42%
Jul 2026
$362.47
$385.21
+6.37%
Jun 2026
$333.00
$362.15
+7.54%
May 2026
$334.89
$336.77
-2.73%
Apr 2026
$354.90
$346.22
-1.61%
Mar 2026
$386.63
$351.87
-9.33%
Feb 2026
$340.82
$388.10
+13.48%
Jan 2026
$328.69
$341.99
+4.47%
Dec 2025
$343.14
$327.35
-5.23%

Amgen Share Price FAQs